Search | HMA-EMA Catalogues of real-world data sources and studies

Interim Analysis of Myocarditis and Pericarditis Associated with COMIRNATY in Persons Less Than 21 Years of Age

Canada

United States

EU PAS number:

EUPAS1000000600

First published:

21/08/2025

Last updated 01/06/2026

Study Discontinued

Post-marketing study to assess serotype-specific effectiveness of Reassortant Rotavirus Vaccine, Live, Oral, Pentavalent (Vero Cell) (ROTATEQ®) in China (V260-077)

China

EU PAS number:

EUPAS36666

First published:

03/09/2020

Last updated 01/06/2026

Study Finalised

Evaluation of the Effectiveness of Implementation of Additional Risk Minimization Measures (aRMM) Materials for Xeljanz® (Tofacitinib) / Rheumatoid Arthritis (RA) indication in Nigeria via a Survey among Prescribers: A Non-Interventional Post Authorization Safety Study (PASS).

Nigeria

EU PAS number:

EUPAS1000000900

First published:

27/05/2026

Last updated 01/06/2026

Study Planned

Retrospective Multi-center Study of the Burden of MBL-producing Enterobacterales in Critically Ill Adults in Spain

Spain

EU PAS number:

EUPAS1000000733

First published:

05/01/2026

Last updated 01/06/2026

Study Planned

Additional risk minimisation measures for Ruconest - European survey of educational materials

European Union

United Kingdom

EU PAS number:

EUPAS1000000680

First published:

21/07/2025

Last updated 01/06/2026

Study Finalised

Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy

European Union

United Kingdom

United States

EU PAS number:

EUPAS1000000891

First published:

23/04/2026

Last updated 01/06/2026

Study Planned

A Post-Marketing Safety Study using a Pregnancy Registry to Evaluate the Safety of Respiratory Syncytial Virus Vaccine (ABRYSVO™) Exposure During Pregnancy (C3671041)

United States

EU PAS number:

EUPAS1000000179

First published:

07/06/2024

Last updated 01/06/2026

Study Ongoing

Real-world Retrospective Study of RSV Hospital Care Burden, HCRU, and Costs in a Multi-country Hospital Database (REACH)

Netherlands

Spain

United Kingdom

EU PAS number:

EUPAS1000000941

First published:

29/05/2026

Last updated 29/05/2026

Study Ongoing

Dutch Haemophilia Registry

Netherlands

First published:

01/02/2024

Last updated 29/05/2026

Data source

Human

Disease registry

Record completeness: 97%

Compare Compare

German Dementia Registry (DEMREG)

Germany

EU PAS number:

EUPAS1000000913

First published:

29/05/2026

Last updated 29/05/2026

Study Ongoing

Remibrutinib in real-world clinical practice: a prospective, multi-country, non-interventional, effectiveness and safety study (REASSERT) - Local adaptation in Germany from global umbrella protocol (CLOU064A2402)

Germany

EU PAS number:

EUPAS1000001003

First published:

29/05/2026

Last updated 29/05/2026

Study Planned

TARGET-EU: Dapagliflozin and major adverse cardiovascular events in type 2 diabetes

Netherlands

Spain

United Kingdom

EU PAS number:

EUPAS1000000979

First published:

29/05/2026

Last updated 29/05/2026

Study Planned

TARGET-EU: Rivaroxaban and risk of major gastrointestinal bleeding in elderly patients with non-valvular atrial fibrillation

Denmark

Netherlands

Spain

EU PAS number:

EUPAS1000001001

First published:

29/05/2026

Last updated 29/05/2026

Study Planned

US Open Claims

United States

First published:

01/02/2024

Last updated 28/05/2026

Data source

Human

Administrative healthcare records (e.g., claims)

Record completeness: 80%

Compare Compare

Oncology EMR - OMOP

United States

First published:

01/02/2024

Last updated 28/05/2026

Data source

Human

Hospital inpatient records Hospital outpatient visit records Specialist ambulatory care records

Record completeness: 90%

Compare Compare

Ambulatory EMR - OMOP

United States

First published:

01/02/2024

Last updated 28/05/2026

Data source

Human

Primary care medical records Specialist ambulatory care records

Record completeness: 97%

Compare Compare

Lithuanian National Data Lake

Lithuania

First published:

14/08/2025

Last updated 28/05/2026

Data source

Human

Administrative healthcare records (e.g., claims) Birth registry Death registry Diagnostic tests or procedures reimbursement Drug registry Hospital discharge records Hospital inpatient records Hospital outpatient visit records Other Pharmacy dispensing records Population registry Primary care medical records Registration with healthcare system Specialist ambulatory care records Vaccination registry

Record completeness: 81%

Compare Compare

Cancer Registry of Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E

Portugal

First published:

01/02/2024

Last updated 28/05/2026

Data source

Human

Disease registry

Record completeness: 88%

Compare Compare

Children's Memorial Health Institute Database

Poland

First published:

27/11/2025

Last updated 28/05/2026

Data source

Human

Hospital discharge records Hospital inpatient records Hospital outpatient visit records Specialist ambulatory care records

Record completeness: 82%

Compare Compare

Pedianet

Italy

First published:

17/10/2022

Last updated 28/05/2026

Data source

Human

Other Population registry Primary care medical records

Record completeness: 90%

Compare Compare

University Medicine, University Hospital Carl Gustav Carus Dresden

Germany

First published:

19/06/2024

Last updated 28/05/2026

Data source

Human

Hospital inpatient records Hospital outpatient visit records

Record completeness: 81%

Compare Compare

University Hospital Antwerp structured data

Belgium

First published:

01/08/2025

Last updated 28/05/2026

Data source

Human

Cancer registry Hospital discharge records Hospital inpatient records Hospital outpatient visit records Other

Record completeness: 95%

Compare Compare

Patient Experience Data in Non‑Interventional Studies Supporting EMA Marketing Authorisation Applications between 2018 and 2023

Netherlands

EU PAS number:

EUPAS1000001011

First published:

28/05/2026

Last updated 28/05/2026

Study Ongoing

Institute for Medicines and Medical Devices (CInMED)

Montenegro

First published:

27/05/2024

Last updated 28/05/2026

Institution Non-EEA National Competent authority Regulatory Authority ENCePP partner

The Danish Multiple Sclerosis Registry

Denmark

First published:

03/11/2025

Last updated 28/05/2026

Data source

Human

Disease registry

Record completeness: 59%

Compare Compare

212853 - Shingrix for intramuscular injection Drug Use Investigation

Japan

EU PAS number:

EUPAS46662

First published:

26/04/2022

Last updated 28/05/2026

Study Finalised

Real-life Enfortumab Vedotin Outcomes as First-line Urothelial Carcinoma Treatment in the Non-interventional Observational and Nationwide French Study

France

EU PAS number:

EUPAS1000000763

First published:

12/11/2025

Last updated 28/05/2026

Study Ongoing

Non-Interventional Postmarketing Safety Study to Evaluate the COMIRNATY 2024-2025 Formula (monovalent KP.2) in the United States

United States

EU PAS number:

EUPAS1000000476

First published:

21/02/2025

Last updated 28/05/2026

Study Ongoing

Enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer previously treated with chemotherapy and immunotherapy: a multicenter, non-interventional study in Italy (EVIDENCE)

Italy

EU PAS number:

EUPAS107848

First published:

22/01/2024

Last updated 28/05/2026

Study Ongoing

Division of Pharmacoepidemiology & Clinical Pharmacology (PECP), Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University

Netherlands

First published:

01/03/2010

Last updated 27/05/2026

Institution Educational Institution ENCePP partner

A pregnancy exposure registry study to assess clinical follow-up and outcomes of pregnancies exposed to ulipristal acetate 30 mg

Austria

Czechia

Finland

France

Germany

Greece

Ireland

Italy

Liechtenstein

Malta

Netherlands

Norway

Poland

Portugal

Romania

Spain

Switzerland

United Kingdom

EU PAS number:

EUPAS33796

First published:

24/02/2020

Last updated 27/05/2026

Study Ongoing

Risk of Malignancy, Major Adverse Cardiovascular Events, and Liver Injury in Patients with Ulcerative Colitis Treated with Mirikizumab versus Other Biologics: A Secondary Database Study in Japan

Japan

EU PAS number:

EUPAS1000001009

First published:

27/05/2026

Last updated 27/05/2026

Study Planned

CLinical oUtcomes before and after biologic treatMent by bIologic class, by iNdividuAl biologic, and by subgroups of baseliNe characTeristics (LUMINANT)

Argentina

Austria

Bulgaria

Canada

Colombia

Denmark

Greece

Ireland

Italy

Japan

Korea, Republic of

Kuwait

Mexico

Portugal

Saudi Arabia

Spain

Taiwan

United Arab Emirates

United Kingdom

United States

EU PAS number:

EUPAS44027

First published:

12/11/2021

Last updated 27/05/2026

Study Finalised

Incidence of Thyroid Neoplasm and Pancreatic Cancer in Type 2 Diabetes Mellitus Patients who Initiate Once Weekly Exenatide Compared with Other Antihyperglycemic Drugs

United Kingdom

EU PAS number:

EUPAS13904

First published:

30/06/2016

Last updated 26/05/2026

Study Discontinued

Evaluating the benefits of RSV maternal vaccination using a Scottish National Dataset. (BORLAND)

United Kingdom

EU PAS number:

EUPAS1000000706

First published:

07/10/2025

Last updated 26/05/2026

Study Planned

An Indian Multicentric, Open Label, Prospective Phase IV Study of Bevacizumab in the Front Line Management of Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer in Real-Life Clinical Practice

India

EU PAS number:

EUPAS3724

First published:

10/09/2013

Last updated 26/05/2026

Study Finalised

LONG-TERM NON-INTERVENTIONAL SAFETY STUDY OF EMICIZUMAB TREATMENT IN PATIENTS WITH MODERATE HAEMOPHILIA A AND SEVERE BLEEDING PHENOTYPE (STUDY BO44691, PASS)

Canada

France

United Kingdom

United States

EU PAS number:

EUPAS1000000174

First published:

13/06/2024

Last updated 26/05/2026

Study Planned

TARGET EU: The risk of angiooedema and other safety events in heart failure patients treated with sacubitril/valsartan compared to angiotensin-converting enzyme inhibitors

Netherlands

United Kingdom

EU PAS number:

EUPAS1000001002

First published:

26/05/2026

Last updated 26/05/2026

Study Ongoing

DARWIN EU® - Characterisation of systemic treatments for the management of ovarian cancer

Denmark

France

Netherlands

Norway

EU PAS number:

EUPAS1000000815

First published:

10/11/2025

Last updated 26/05/2026

Study Finalised

Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie (Embryotox), Charité-Universitätsmedizin, Berlin

Germany

First published:

22/02/2010

Last updated 22/05/2026

Institution Educational Institution ENCePP partner

Search all content

Results(4675)